ChromaDex® Acquires Spherix Consulting

                    ChromaDex® Acquires Spherix Consulting

- Spherix Consulting Brings Technical and Regulatory Services to Further Build
ChromaDex's Offering of Science-Based Solutions -

PR Newswire

IRVINE, Calif., Dec. 3, 2012

IRVINE, Calif., Dec. 3, 2012 /PRNewswire/ -- ChromaDex^® Corporation (OTCQB:
CDXC) ("ChromaDex"), an innovative natural products company that provides
proprietary, science-based solutions and ingredients to the dietary
supplement, food & beverage, animal health, cosmetic and pharmaceutical
industries, and marketer of its branded, patented pterostilbene, pTeroPure^®,
announced today the completion of the acquisition of Spherix Consulting, Inc.,
a subsidiary of Spherix, Inc.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

As a result of the transaction, Spherix Consulting became a wholly-owned
subsidiary of ChromaDex. Spherix Consulting will continue to maintain offices
in the greater Washington, D.C. area. As a leader in scientific and regulatory
consulting, Spherix Consulting has a well-established list of Fortune 1000
customers. The transaction is expected to result in an immediate increase in
revenue for ChromaDex. 

Spherix Consulting provides its clients in the food, supplement and
pharmaceutical industries with effective solutions to manage potential health
and regulatory risks. Its science-based solutions are for both new and
existing products that may be subject to product liability and/or exposed to
changing scientific standards or public perceptions; literature evaluations;
and design and assessment of pre-clinical and clinical safety testing. Spherix
Consulting specializes in regulatory submissions for food and dietary
supplement ingredients (GRAS, NDIN, Food Additive Petitions, Novel Food
Petitions). For its clients involved in drug development within the
pharmaceutical industry, Spherix provides similar services as well as
risk-based strategies, including intellectual property data and compliance gap
identification, due diligence assessments and IND writing.

The acquisition will complement and expand ChromaDex's leadership in the
reference standards and services business. By providing a more comprehensive
suite of science-based and regulatory services, ChromaDex will to able to more
efficiently advance products in the dietary supplement, food & beverage,
animal health, cosmetic and pharmaceutical markets.

Commenting on the announcement, Frank Jaksch, CEO and co-Founder of ChromaDex,
stated, "Spherix Consulting is a premier provider of product regulatory
approval and scientific advisory services. Given the rapidly changing
regulatory environment, these services have never been more critical for
suppliers, manufacturers and retailers. By acquiring Spherix Consulting we
provide this valuable expertise to better support our customers' product
development outcomes."

Claire Kruger, who will continue as President of Spherix Consulting, added,
"Together, Spherix Consulting and ChromaDex will provide a comprehensive
platform of services for our clients that is both efficient and effective. Our
unparalleled industry expertise and complementary offerings will provide our
customers with enhanced services and better access to the information they
need to make science-based decisions."

About ChromaDex^®:

ChromaDex, Inc. is an innovative natural products company that provides
proprietary, science-based solutions and ingredients to the dietary
supplement, food & beverage, animal health, cosmetic and pharmaceutical
industries. ChromaDex's pipeline of proprietary products includes patented
pTeroPure^® pterostilbene, which was named the 2010 North American Most
Promising Ingredient of the Year by the independent research company Frost &
Sullivan. The company has also launched ProC3G™, a natural black rice extract
containing 40% cyanidin-3-glucoside and is in the process of developing
Nicotinamide Riboside, a novel next-generation B-vitamin. All products are
backed with extensive scientific research and intellectual property.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are
"forward-looking statements" as that term is defined under the Private
Securities Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words
of similar meaning. Many factors could cause our actual activities or results
to differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described in the
companies' filings with the Securities and Exchange Commission, and risks
inherent in funding, developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments. In addition,
forward-looking statements may also be adversely affected by general market
factors, competitive product development, product availability, federal and
state regulations and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements contained in
this press release speak only as of the date the statements were made, and the
companies do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.

ChromaDex Media Inquiries:
Chandler Chicco Agency
Keshia Cain, Media Specialist
310-309-1017
kcain@ccapr.com

ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

ChromaDex Contact:
Laura Carney, Executive Assistant
949-419-0288
laurac@chromadex.com

SOURCE ChromaDex
 
Press spacebar to pause and continue. Press esc to stop.